NeurAxis, Inc. - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
NRXS NYSE American 3841 neuraxis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Nov 12th, 2025 6:00 am
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues - Nov 11th, 2025 5:00 am
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025 - Nov 4th, 2025 6:30 am
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population - Oct 24th, 2025 6:00 am
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Sep 18th, 2025 6:00 am
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis - Sep 17th, 2025 3:53 am
Top Research Reports for Alphabet, IBM & Merck - Sep 16th, 2025 2:42 pm
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth - Aug 18th, 2025 12:27 pm
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues - Aug 12th, 2025 5:00 am
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025 - Aug 5th, 2025 6:30 am
The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technologies and NeurAxis - Jun 27th, 2025 2:53 am
Top Stock Reports for Microsoft, NVIDIA & Bank of America - Jun 26th, 2025 2:34 pm
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - Jun 17th, 2025 6:00 am
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS - Jun 10th, 2025 6:00 am
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - May 27th, 2025 6:00 am
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - May 22nd, 2025 11:03 am
NeurAxis Announces $5.0 Million Registered Direct Offering - May 21st, 2025 5:00 am
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - May 20th, 2025 6:00 am
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones - May 15th, 2025 10:06 am
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues - May 12th, 2025 6:15 am